Fund moves
18 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 1, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 3, 2026 · Filed Mar 4, 2026
Charles River Laboratories's Corp Strategy & Develop paid $4.4K out of pocket for Charles River Laboratories shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$4,364
Shares × reported transaction price
<$25K
+0.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($3.56M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-31. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
13 days after results of Feb 18, 2026, 65 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $175.69 on Mar 3, 2026, 76% above its 52-week low and 23% below its high, after a 20% drop over the previous 30 trading days
52-week range $99.75 (Apr 11, 2025) to $226.77 (Jan 21, 2026), 60% of the way up, from 251 adjusted closes. 30 trading days earlier: $219.70 on Jan 16, 2026. Describes the past only, not a forecast
RSI 45, 3% above its 200-day average, 11% under its 50-day average, 23% below the 52-week high, 20-day volatility 62% a year, against the S&P 500: −15 points over 1 month, −1 points over 3 months, +2 points over 6 months
From the adjusted closes up to Mar 3, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any CRL insider since Feb 2025. Joseph W Laplume's first open-market purchase of CRL in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −15.8% | −2.2% | −13.6% |
| 30 days | −7.2% | −3.3% | −3.9% |
| 90 days | −0.8% | +10.7% | −11.5% |
| 180 days | +55.7% | +11.8% | +43.9% |
Past results only. Not a forecast.
Fund moves
18 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 1, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Mar 4 · filed 1 day later
Gift or transfer — classified separately from trades.
Insider filing
Traded Mar 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.